Promise of Improvements for the Treatment of Infantile Diarrhea
NEW BERN, N.C., March 11, 2015 /PRNewswire/ -- Enteric Solutions Corporation (ESC) announced today that the Internal Revenue Service has awarded the 501(c)(3) nonprofit status to the company. ESC expects to commence a fundraising campaign in the second quarter of 2015.
ESC develops innovative pharmaceutical technologies for the treatment of enteric (intestinal) disease in developing countries and beyond.
In particular, diarrhea is a symptom of infection and causes rapid depletion of water and sodium - both of which are necessary for life. Reports of the annual estimated number of diarrhea caused deaths in children less than 5 years old vary between 578,000 and 1.5 million.
"Obtaining 501(c)(3) status is an essential milestone for ESC," remarked President and Founder, Luis Molina, Ph.D. "This opens many avenues for us to expand fundraising activities, form partnerships and subsequently implement technical development plans and clinical studies."
Oral rehydration solutions (ORS) over the last 40 years have shown a dramatic reduction in mortality without affecting severity and duration of diarrhea. Addition of zinc (Zn) reduced severity and duration of the condition, and addition of amylase resistant starch (RS) reduced stool output.
Therefore ESC intends to prepare improved, state-of-the-art formulations based on the ORS composition and show superiority in the clinical arena, prior to market penetration. For simplicity, the proposed active components of ESC's formulation are as follows: ORS+Zn+RS.
ESC will develop tactics to improve delivery and uptake of the formulations, smaller ORS+Zn+RS packets and flavored formulas. These components will be presented in diarrhea treatment packages, accompanied by educational materials.
Additional uses for improved ORS solutions are, for example, in the large outbreak of Ebola in Africa. Ebola is a viral infectious disease which, while not primarily affecting the gastrointestinal tract, can cause diarrhea. Among the supportive treatment provided to patients in Nigeria in 2014, ORS was shown to rebalance fluids and salts once the patients were able to eat and drink on their own.
About ESC
ESC is a virtual, early stage pharmaceutical company focused on the development and subsequent marketing of supplements and products for the treatment of enteric diseases in developing countries.
For more information, visit www.entericsolutions.com
Contact information of Dr. Molina:
Dr. Luis Molina
919 623-4108
Email
SOURCE Enteric Solutions Corporation
Share this article